UH CLEVELAND MEDICAL CENTER
The Sunshine Act requires manufacturers to report payments to teaching hospitals as institutions, separately from payments to individual physicians. These figures are money reported to the hospital itself — most of it research funding and grants, not compensation to any named doctor.
- Total reported
- $104M
- Transactions
- 13,101
- Companies
- 40
- Average per transaction
- $7,939
Who reported the payments
| Amgen | $14,179,626 |
| Merck | $5,997,740 |
| AVEO Pharmaceuticals, Inc. | $5,750,937 |
| AbbVie | $4,795,791 |
| Seagen Inc. | $4,638,010 |
| Novartis | $4,153,055 |
| Eli Lilly | $3,589,399 |
| Gilead | $3,323,222 |
| Medtronic | $2,608,688 |
| Takeda Pharmaceuticals U.S.A., Inc. | $2,359,862 |
| AstraZeneca | $2,114,874 |
| Pfizer | $2,092,126 |
| Janssen Research & Development, LLC | $2,081,217 |
| Vertex | $1,900,690 |
| Steris Corporation | $1,880,646 |
| Boston Scientific | $1,861,615 |
| E.r. Squibb & Sons, L.L.C. | $1,860,522 |
| Regeneron | $1,848,763 |
| Siemens Medical Solutions USA, Inc. | $1,726,683 |
| Cochlear Americas | $1,607,912 |
| BD | $1,559,718 |
| Genentech, Inc. | $1,300,835 |
| Abbott | $1,278,475 |
| Astrazeneca UK Limited | $1,042,515 |
| Glaukos Corporation | $826,876 |
| CSL Behring | $798,418 |
| Bristol Myers Squibb | $742,773 |
| Blue Earth Diagnostics | $684,356 |
| Daiichi Sankyo Inc. | $675,917 |
| Stryker | $672,488 |
| Boehringer Ingelheim | $670,919 |
| Tesaro, Inc. | $648,417 |
| Sanofi Pasteur Inc. | $577,165 |
| Bayer | $566,708 |
| Incyte Corporation | $546,888 |
| Ultragenyx Pharmaceutical Inc. | $525,297 |
| Argenx US, Inc. | $518,741 |
| Heartflow, Inc. | $448,990 |
| Alkermes, Inc. | $432,352 |
| Sanofi | $429,460 |